The Future of Samagletide

The first samagletide product, Ozempic, was approved in 2017. Novo just has a bunch of data. So perhaps doctors and patients would feel more comfortable with what we know about the safety of Samagletide. We know that trials have shown that it cuts cardiovascular risks in people with diabetes; they have a cardiovascular outcomes trial for people with obesity reading out pretty soon this year.